- August 1996: Cel-Sci signs agreement with U.S. Navy on a malaria vaccine collaboration.
- October 1996: Cel-Sci and Northeastern Ohio Universities College of Medicine sign an agreement to develop a herpes virus vaccine.
- January 1997: Cel-Sci receives a Maryland state grant to develop a test for tuberculosis.
- July 1997: Cel-Sci announces development of a potential AIDS vaccine for worldwide use.
- September 1997: Cel-Sci signs agreement with the National Cancer Institute to test a cancer immunotherapy for prostate and breast cancer.
- October 1997: Cel-Sci says LEAPS vaccine technology effective against multi-drug resistant tuberculosis.
- April 1998: Cel-Sci introduces LEAPS vaccine technology at a scientific conference.
- May 1998: Cel-Sci receives government grant for vaccine against herpes virus.
- July 1998: Cel-Sci receives more State of Maryland grant money for tuberculosis test.
- October 1998: Cel-Sci and University of Nebraska collaborate on HIV vaccine.
- Jan. 1999: State of Maryland funds Cel-Sci effort to develop tuberculosis vaccine.
- September 1999: Cel-Sci creates a separate company, MaxPharma, to develop the LEAPS. vaccine technology.
- November 1999: Cel-Sci collaborates with John Hopkins University on a vaccine for heart disease (myocarditis.)
- June 2000: Cel-Sci and the National Cancer Institute form collaboration to develop HIV vaccine.
- October 2001: Cel-Sci and BioMedex partner to develop rapid screening test for anthrax.
- December 2002: Cel-Sci signs agreement with University of Arkansas Medical Center to evaluate Cel-1000 against genital chlamydia.
- January 2003: Cel-Sci says Cel-1000 has potential as a broad bioterrorism vaccine.
- April 2003: Cel-Sci and Northeastern Ohio Universities College of Medicine receive grant to develop Cel-1000 against viral encephalitis.
- April 2003: Cel-Sci receives grant from National Institutes of Health to develop vaccine treatment against heart disease.
- April 2003: Cel-Sci says Cel-1000 effective against virus that causes Severe Acute Respiratory Syndrome (SARS).
- June 2003: Cel-Sci says Cel-100 has potential as vaccine adjuvant.
- June 2003: Cel-Sci signs agreement with the U.S. Army and the National Institutes of Health to develop a vaccine against SARS, Smallpox, Vaccinia and West Nile Virus.
- April 2005: Cel-Sci says Cel-1000 effective against viral encephalitis.
- December 2005: Cel-Sci signs agreement with National Institute of Allergy and Infectious Disease to test Cel-1000 against avian flu virus.
- September 2008: Cel-Sci says new vaccine, Cel-2000, active against rheumatoid arthritis.
- April 2009: Cel-Sci says LEAPS vaccine technology shows potential as a treatment for H1N1 virus.
- November 2009: Cel-Sci and Johns Hopkins University School of Medicine collaborate to test LEAPS -H1N1 vaccine as treatment against H1N1 flu.
Cel-Sci's History of Disappearing Drugs: BioBuzz
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.